anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
AIM: To examine and map alcohol consumption in children and adolescents with chronic pain (CP).
METHOD: A scoping review of international databases (CINAHL, WOS, PubMed, PsycINFO, Scopus, Embase, and MEDLINE) and grey literature was conducted between September 2022 and February 2023. Documents addressing the relationship between alcohol consumption and CP in children and adolescents, published in English and Spanish between 2012 and 2023, were included. Those papers with a population suffering from CP derived from neurodegenerative diseases, chronic infectious diseases or cognitive impairment were excluded. We assessed the level of evidence (LE) and the degree of recommendation (DR) of the studies included in accordance with the Scottish Intercollegiate Guidelines Network. Finally, 11 documents were considered out of the 479 reviewed.
RESULTS: The relationship between substance consumption and CP in adolescents is a scarcely investigated topic. While there is a trend towards lower rates of alcohol consumption in youth with pain, there is evidence suggesting an association, particularly in cases of intense pain. The use of various substances, both legal and illegal, for pain management underscores the importance of comprehensively addressing this phenomenon in this population.
CONCLUSIONS: Further research is needed to assess the relationship between alcohol consumption in children and adolescents with CP.
Systems, techniques, and methods for estimating the metabolic state or flux, e.g. the body energy state (BES) of a patient, are disclosed. The BES provides a deep insight into the nutritional needs of the patient, thus allowing for a sort of exquisite glycemic control with regard to the patient. The invention discloses systems and methods for estimating fractional gluconeogenesis. The invention also discloses systems and methods for estimating and targeting patient blood lactate concentration, both as a target itself and as an intermediate step to estimating and targeting patient fractional gluconeogenesis glucose production. Nutritional support methods and formulations are also disclosed. The invention is suitable for any sort of patient, including those who are injured, such as with traumatic brain injury, ill, or have other conditions that stress the metabolic system.
Telehealth-delivered inductive reasoning training will focus on improving the ability to solve problems that require linear thinking and that follow a serial pattern or sequence. Participants will be taught strategies to identify patterns to solve problems. These problems involve identifying the pattern in series of numbers and letters, or recognizing patterns in everyday activities, like dosing for medications. Training will consist of ten training sessions, over 5 weeks, and will be conducted over Zoom. Each training session is 60-75 minutes long and typically consists of (a) 10 minutes of introductory training exercises for basic mental abilities, such as finding patterns in schedules, (b) training exercises for everyday tasks, such as filling out medication charts, recycling charts, and understanding medicine bottle labels, and (c) a 20-question practice assessment.
The invention discloses a natural depilatory agent. The depilatory agent is mainly used for removing underarm hairs, arm hairs and leg hairs. The depilatory agent consists of a corn extract, natural collagen, a green tea extract, water, honey, essence and green pigment. The agent is made of extracts of natural plants and any harmful ingredients are not added. The depilatory agent is a natural water-soluble product. The depilatory agent is free from peculiar smell, soft and is capable of conducting deep hair removal and uprooting hairs from hair follicles instantly and completely. Skins cannot be hurt and the depilatory agent is an ideal depilatory product.
Patients with histological or cytological proven metastatic breast cancer were recruited. The previous hormonal therapy for metastatic breast cancer or cytotoxic therapy was allowed. The Her2/Neu over-expressive status should be negative. Patients with brain metastasis are excluded.
The present invention relates to syrup for treating cough and asthma and a preparation technology thereof. The recipe of the syrup comprises Chinese medicine preparations such as prepared arisaema, stemona root, flat fritillary, almonds, loquat leaves, balloonflower, liquorice, etc. The preparation technology comprises: the houttuynia is individually pulverized and is immersed in water for extracting medicine liquor; the medicine liquor is boiled for five minutes; the rest Chinese medicine is pulverized and immersed in the water for the cold extraction of medicine; the medicine is heated and concentrated into medicine liquor; two kinds of medicine liquor are mixed; a flavouring agent is added for vacuum filtration; after being bottled, the medicine liquor is radiated for sterilization. The effective rate of the present invention for cough relief, phlegm discharge and paediatric whooping cough is 100%, and an effective rate for stopping asthma is 90%. After the syrup is taken for one month, a cure rate for senile bronchitis is 87%; the syrup has an obvious antiphlogosis effect; the syrup can effectively control cough and asthma due to pulmonary diseases; the syrup has high cough relief speed, and can take effect within ten minutes for achieving the efficacy of removing lung diseases, stopping the cough, eliminating phlegm, relieving the asthma, regulating qi and removing inflammation. The present invention has the advantages of no side effect, no influence on the administration of diabetic patients, good mouth feel and easy administration by children.
In this randomized clinical trial of 4 lining materials have been applied in deep caries teeth in stepwise excavation. The common material which is applied as a liner over the remained caries in SE is Calcium Hydroxide(CH). There are several reports of the solubility of this liner over time which could interact with sealing of the cavity in long term. It seems that a material with antibacterial activity, good sealing ability and suitable mechanical properties could cause SE be done efficiently with good prognosis.

MTA is a biomaterial that has been introduced since 1993 with antibacterial property and good sealing ability. A New Endodontic Cement, Calcium Enriched Mixture (CEM) cement with good antibacterial effect like CH with sealing ability that is proposed to be similar to MTA according to its double sealing property. CEM cement has been suggested as a suitable material in pulp capping of permanent molars with irreversible pulpitis.
The normal term infant at birth is able to suck-swallow in a coordinated manner sufficient for nutritional intake and protection of the upper airway. The integrity of this post-natal behavior is dependent on intrauterine growth and function of the orofacial, pharyngeal and laryngeal structures of the upper aerodigestive system. The integrity of these structures not only ensures functional postnatal ingestive skills, but also contributes to the prenatal development of the gastrointestinal tract, regulation of amniotic fluid and composition, and recirculation of solutes. This developing system thus has importance in both fetal and neonatal well-being. However, few biometric or biophysical data exist detailing the normal patterns of growth and development of the aerodigestive structures in the human fetus. Further, factors that contribute to abnormal fetal and neonatal deglutitive responses are not fully known.

The purpose of this study is to establish the first anthropomorphic database on the development of aerodigestive structures in the fetus and, through sonographic biophysical profiles, examine the significance of fetal ingestive behaviors as predictors of postnatal feeding skills in at-risk infants. A detailed cross-sectional study of the development of the fetal upper aerodigestive tract and analysis of the progression of deglutitive skills over the course of gestation may lead to the early identification of factors contributing to neonatal swallowing dysfunction and other developmental delays. These data may provide insights into underlying intrauterine conditions associated with infant feeding difficulties. Resulting two- and three-dimensional ultrasonic data on the structural development of the upper aerodigestive system, coupled with biophysical data may be useful predictors of neonates at risk for nutritional and pulmonary sequelae. Further, sequential indices of normal swallowing-sucking skills may guide post-natal decisions for feeding "readiness" and advance the care of the premature, at-risk infant.
Persons living with HIV and hypertension aged 18 years and above will receive integrated screening (blood pressure measurement) and treatment of hypertension in their respective models of HIV care. The models of HIV care include the clinic based HIV care and community based HIV care. Treatment of hypertension will be based on a simplified one page protocol adapted from the WHO HEARTS packages for hypertension control. Health workers will be trained to titrate hypertension medications for PLHIV with hypertension using the three medications is a step wise manner: Amlodipine, Hydrochlorothiazide and Losartan.
The present invention relates to a system and method of transmitting an emergency condition using a wireless sensor network that transmits a user's emergency condition using a wireless sensor network. A wireless sensor network communication device integrated with a biological sensor is attached to a user's body in order to gather user's biological information, and transmits the user's biological information through the wireless sensor network. A repeater receives the biological information from the communication device, and sends the received biological information by using a routing protocol of the wireless sensor network. A management server receives the biological information through the repeater, analyzes the biological information, and transmits a warning signal to a user or takes emergency measures. Therefore, it is possible to detect and cope with sudden physical problems, which are generated during user's exercises and outdoor activities, at an early stage. As a result, it is possible to significantly contribute to the prevention and reduction of danger for the weak and the elderly, and a user who is to be taken care of.
Hodgkin lymphoma (HL), an uncommon but significant subtype of lymphoma, is divided into classical HL (cHL) and nodular lymphocyte predominant HL (NLPHL). Progress has been made in cHL therapy resulting in 5-year failure free survival rates between 61%-89% even in the setting of advanced stage or bulky disease. Patients who relapse however, have a variable prognosis ranging from a 8-year overall survival rate of less than 8% for patients who never achieve a remission to 54% for patients with a complete remission lasting greater than 12 months. High dose chemotherapy with autologous stem cell support is the standard of care for patients with relapsed cHL but for those that relapse despite aggressive salvage therapy 20 - 50%, with median remission durations of approximately 6 months. Furthermore, a subset of relapsed HL patients may not be candidates for aggressive salvage regimens. These novel salvage therapies are needed for relapsed/refractory cHL, especially agents without serious late toxicities are particularly attractive in this disease. Advances in the understanding of HL pathogenesis and lenalidomide's mechanisms of action provide substantial rationale for evaluating lenalidomide in HL patients.
BACKGROUND/AIMS: Having type 2 diabetes (T2D) in combination with being overweight results in an additional increase in cardiovascular disease (CVD) risk. In addition, T2D and obesity are associated with increased levels of total homocysteine (tHcy), possibly contributing to the CVD risk. Weight loss dieting has positive effects on several CVD risk factors, but whether it affects tHcy remains unclear. Therefore, the aim of this study was to determine the effect of a calorie restricted diet on tHcy in overweight people with T2D.
METHODS: In this post-hoc analysis of the POWER study, adults with T2D and a BMI greater than 27 kg/m² were included from the outpatient diabetes clinic of the Erasmus Medical Center, Rotterdam. The patients were subjected to a very low-calorie diet with fortified meal replacements for 20 weeks. Before and after this intervention, blood samples were collected to measure tHcy and other CVD risk factors like glycaemic and lipid parameters.
RESULTS: 161 overweight participants with T2D were included, with a mean age of 54 years (range 26-74), mean weight of 104.6 ± 19.9 kg and mean HbA1c of 62.7 ± 14.3 mmol/mol. At baseline, men displayed higher tHcy than women, and tHcy level was positively correlated with body weight and triglyceride levels, while it was negatively correlated with renal function and HDL cholesterol. During the intervention, bodyweight was reduced by a mean of 9.7% (from 104.6 ± 19.9 to 94.5 ± 18.1 kg p < 0.001), and all measured glycaemic and lipid blood parameters improved significantly. However, tHcy remained unchanged (from 12.1 ± 4.1 to 12.1 ± 4.2 umol/L, p = 0.880). The change in tHcy during the intervention was negatively associated with the change in weight and BMI (p = 0.01 and p = 0.008, respectively). People who lost < 10 kg (n = 92) had a mean tHcy change of -0.47 umol/L, while people who lost more than ≥ 10 kg (n = 69) had a mean tHcy change of 0.60 umol/L (p = 0.021).
CONCLUSION: In conclusion, our data show that a calorie restricted diet does not affect tHcy in people with T2D and obesity, despite the use of meal replacements fortified with folic acid and vitamin B12. Our data showed a negative correlation between change in tHcy levels and weight loss, suggesting that people who lost more weight (> 10 kg) showed an increase in tHcy. Future studies should explore the potential increase in tHcy induced by weight loss dieting and target the question if tHcy reduction strategies during weight loss could be clinically beneficial.
The investigators propose to screen patients with bipolar depression I or II, who are already on acceptable mood stabilization. They may or may not be on antidepressants at the time of screening but subjects on antidepressants would be taken off them before completing the screening phase. Those patients who have a depression of at least moderate severity without significant symptoms of activation or mania will be started on a course of open label TMS treatment of up to 35 sessions. Safety and efficacy assessments will be done weekly. Patients will complete a course of treatment when they meet remission criteria (MADRS score \< 10) or at the end of 30 treatments, whichever comes first. Patient who are still judged to be improving between treatment 25 and treatment 30 will be eligible to complete up to five addition treatments as the discretion of each site's principal investigator. Patients who meet response criteria (MADRS score decreases by at least 50%) will complete the full course of 30 to 35 TMS sessions. Patients will be withdrawn for safety concerns, particularly the onset of activation suggestive of mania or a mixed state.

Patients who meet response or remission criteria will be followed monthly for up to six months to evaluate the durability of response. They will be on standard mood stabilizing medications and psychotherapy per their clinician's discretion.
External neuromuscular electrical stimulation was applied to the patients in supine position. It was applied for 30 minutes 3 days a week for 8 weeks. This stimulation consists of a total of eight external electrodes, including 2 sheaths wrapped around the thigh area and 4 electrodes for each leg. Electrodes were placed on the anterior and posterior proximal thighs, buttocks, and outside of the hips. The treatment protocol was applied with symmetrical biphasic current at a frequency of 50 Hertz (Hz), with stimulation and rest periods of 5 seconds of contraction and 5 seconds of rest.
Patients with MCI (Mild Cognitive Impairment) will undergo intervention using exercises by imitation from individuals residing in the facility but without cognitive impairment. They will participate in a 5-week exercise program based on observation and action. Data will be collected at the beginning and end of the program.
This is a two-way (retrospective+prospective) cohort study of patients with primary biliary cholangitis (PBC) and autoimmune hepatitis (AIH) infected with COVID-19. Enrolled PBC and AIH patients in clinical diagnosis and treatment at Beijing Ditan Hospital, Capital Medical University from January 2021 to December 2023. After enrollment, the demography data of patients, the treatment information of PBC and AIH patients, the use of ursodeoxycholic acid (UDCA) and immunosuppressants, COVID-19 vaccination, COVID-19 infection and incidence, clinical symptoms, clinical biochemistry, liver imaging, lung imaging, COVID-19 nucleic acid, COVID-19 antibody, and the incidence and treatment information of COVID-19 from January 2022 to pre enrollment were collected. Meanwhile, the corresponding treatment and clinical observation of PBC and AIH were continued, and the occurrence and incidence of COVID-19 infection were observed. For patients with COVID-19 infection during the prospective observation period, COVID-19 infection, onset and treatment were observed, including clinical symptoms, signs, heart, lung imaging, COVID-19, clinical biochemistry, disease degree, virus negative, hospital stay and prognosis. This study is aim to compare the difference of COVID-19 infection rate, disease severity, clinical biochemical indicators, hospital stay and prognosis between UDCA treated and non UDCA treated patients, and to study the impact of UDCA on the occurrence, incidence and prognosis of COVID-19 infection.
Monitoring the quality of sleep of an individual is essential for ensuring one's overall well-being. The existing methods for non-apnea sleep arousal detection are manual. A system and method for the non-apnea sleep arousal detection has been provided. The method uses a feature engineering based binary classification approach for distinguishing non-apnea arousal and non-arousal. A training data set is prepared using a plurality of physiological signals. A plurality of features are derived from the training data set. Out of those only a set of features are selected for training a plurality of random forest classifier models. A test sample is then provided to the plurality of random forest classifier models in the instances of fixed duration. This results in generation of prediction probabilities for each instances. The prediction probabilities are then used to predict the probabilities of non-apnea sleep arousal in the test sample.
PURPOSE: To prepare a pharmaceutical composition, comprising a specific compound or its acid addition salt and useful for treatment, etc., of arteritis, especially the arteritis in lower limbs, disorders in cerebral circulation, especially cerebral senile disorders or migraine, visual disorders, e.g. retinopathy caused by the vascular system without manifesting hypotensive actions when administered. CONSTITUTION: This pharmaceutical composition comprises a compound represented by formula I [A is vinylene or dimethylene; (q) is 0 or 1; R is a lower alkyl which may contain NH2 ; X is S and R1 is H or X is NH and R1 is a group represented by formula II (R2 is OH or an alkoxy; R3 is H, an alkyl, etc.)] or its acid addition salt as an active ingredient. (S,S,S)-2- 2-[3-P henyl-1(ethoxycarbonyl) propylamino] propionyl}-3carboxy-2azabicyclo[2.2.2] octane is more preferred as the compound represented by formula I. The compound represented by formula I is usually administered in 0.001-10mg dose at a time.
A proprioceptive training regimen will established with Swiss balls. The proprioceptive activities are advanced on a weekly basis in order to test the patient's balance in response. Patients have training in three stages: beginning, intermediate, and advanced. Each exercise is performed as 3x10 repetitions. Between sets, 2-3 minutes rest breaks is given. The beginning phase is applied in the 1st and 2nd weeks, the intemediate phase in the 3rd and 4th weeks, and the advanced phase in the 5th and 6th weeks.
The present invention relates to a computer-implemented methods and apparatus for remote cognitive and/or perceptual testing using a computer network having a remote computer geographically separate from an administering computer. The remote cognitive and/or perceptual testing includes administering a set of cognitive and/or perceptual tests, obtaining a performance response of the person to the tests and uploading the testing information via the computer network. The tests may be administered a number of times to evaluate one or more cognitive skills and/or perceptual abilities. Parallel to the testing, a therapy may be administered. The method may also include monitoring the performance of the person on the tests. The computer-implemented method may additionally include administering a set of initial tests before therapy inception to assess a person's intrinsic cognitive skills and/or perceptual abilities. The results of the initial testing and testing during therapy may be entered into a database. The database may be built from the performance response of multiple people and may be useful in predicting efficacy of a proposed therapy.
Participants will switch from an optimized dose of intravenous infliximab to an optimized dose of subcutaneous infliximab. This means the participants will inject 120 mg subcutaneous infliximab every week.
Sarcopenia increases the risk of a number of deleterious health conditions and represents a major financial cost to our healthcare system. Among older adults who are hospitalized, those with sarcopenia on admission are 5-fold more likely to incur higher hospital costs than those without. The operational definition of sarcopenia is defined as meeting the criteria for all of the following: low muscle strength, low muscle quantity or quality, and low physical performance. The diagnosis of sarcopenia requires techniques that are both expensive and operator-dependent. Simple measurements, such as BMI, do not necessarily identify sarcopenia. Importantly, current techniques can only identify sarcopenia after a physical/functional impairment has occurred. Skeletal muscle amino acid kinetics predict muscle health and functionality. Altered amino acid kinetics lead to decrements in muscle mass, quality, and performance. Muscle response to circulating essential amino acids (EAA) determines muscle amino acid kinetics. Thus, this study proposes to characterize skeletal muscle amino acid kinetics to an EAA challenge, i.e., an oral amino acid tolerance test (OATT), in order to determine the state of muscle health. Analogous to the oral glucose tolerance test (OGTT) used to characterize alterations in glucose metabolism, the proposed OATT represents a potential low-cost solution to classifying patients' skeletal muscle health. The extrapolation of this work is the development of a simple analytical tool that would provide clinicians the ability to discern alterations in muscle amino acid kinetics prior to a loss of function.